1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Market Analysis by Type
  • 1.3.1 Overview: Global Fluzoparib Consumption Value by Type: 2021 Versus 2025 Versus 2032
  • 1.3.2 50 Mg
  • 1.3.3 100 Mg
• 1.4 Market Analysis by Sales Channels
  • 1.4.1 Overview: Global Fluzoparib Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
  • 1.4.2 Hospital
  • 1.4.3 Retail
  • 1.4.4 Online
• 1.5 Market Analysis by Application
  • 1.5.1 Overview: Global Fluzoparib Consumption Value by Application: 2021 Versus 2025 Versus 2032
  • 1.5.2 Ovarian Cancer Treatment
  • 1.5.3 Breast Cancer
  • 1.5.4 Prostate Cancer
  • 1.5.5 Pancreatic Cancer
  • 1.5.6 Others
• 1.6 Global Fluzoparib Market Size & Forecast
  • 1.6.1 Global Fluzoparib Consumption Value (2021 & 2025 & 2032)
  • 1.6.2 Global Fluzoparib Sales Quantity (2021-2032)
  • 1.6.3 Global Fluzoparib Average Price (2021-2032)

2 Manufacturers Profiles

• 2.1 Jiangsu Hengrui Pharmaceuticals
  • 2.1.1 Jiangsu Hengrui Pharmaceuticals Details
  • 2.1.2 Jiangsu Hengrui Pharmaceuticals Major Business
  • 2.1.3 Jiangsu Hengrui Pharmaceuticals Fluzoparib Product and Services
  • 2.1.4 Jiangsu Hengrui Pharmaceuticals Fluzoparib Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.1.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates

3 Competitive Environment: Fluzoparib by Manufacturer

• 3.1 Global Fluzoparib Sales Quantity by Manufacturer (2021-2026)
• 3.2 Global Fluzoparib Revenue by Manufacturer (2021-2026)
• 3.3 Global Fluzoparib Average Price by Manufacturer (2021-2026)
• 3.4 Market Share Analysis (2025)
  • 3.4.1 Producer Shipments of Fluzoparib by Manufacturer Revenue ($MM) and Market Share (%): 2025
  • 3.4.2 Top 3 Fluzoparib Manufacturer Market Share in 2025
  • 3.4.3 Top 6 Fluzoparib Manufacturer Market Share in 2025
• 3.5 Fluzoparib Market: Overall Company Footprint Analysis
  • 3.5.1 Fluzoparib Market: Region Footprint
  • 3.5.2 Fluzoparib Market: Company Product Type Footprint
  • 3.5.3 Fluzoparib Market: Company Product Application Footprint
• 3.6 New Market Entrants and Barriers to Market Entry
• 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

• 4.1 Global Fluzoparib Market Size by Region
  • 4.1.1 Global Fluzoparib Sales Quantity by Region (2021-2032)
  • 4.1.2 Global Fluzoparib Consumption Value by Region (2021-2032)
  • 4.1.3 Global Fluzoparib Average Price by Region (2021-2032)
• 4.2 North America Fluzoparib Consumption Value (2021-2032)
• 4.3 Europe Fluzoparib Consumption Value (2021-2032)
• 4.4 Asia-Pacific Fluzoparib Consumption Value (2021-2032)
• 4.5 South America Fluzoparib Consumption Value (2021-2032)
• 4.6 Middle East & Africa Fluzoparib Consumption Value (2021-2032)

5 Market Segment by Type

• 5.1 Global Fluzoparib Sales Quantity by Type (2021-2032)
• 5.2 Global Fluzoparib Consumption Value by Type (2021-2032)
• 5.3 Global Fluzoparib Average Price by Type (2021-2032)

6 Market Segment by Application

• 6.1 Global Fluzoparib Sales Quantity by Application (2021-2032)
• 6.2 Global Fluzoparib Consumption Value by Application (2021-2032)
• 6.3 Global Fluzoparib Average Price by Application (2021-2032)

7 North America

• 7.1 North America Fluzoparib Sales Quantity by Type (2021-2032)
• 7.2 North America Fluzoparib Sales Quantity by Application (2021-2032)
• 7.3 North America Fluzoparib Market Size by Country
  • 7.3.1 North America Fluzoparib Sales Quantity by Country (2021-2032)
  • 7.3.2 North America Fluzoparib Consumption Value by Country (2021-2032)
  • 7.3.3 United States Market Size and Forecast (2021-2032)
  • 7.3.4 Canada Market Size and Forecast (2021-2032)
  • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

• 8.1 Europe Fluzoparib Sales Quantity by Type (2021-2032)
• 8.2 Europe Fluzoparib Sales Quantity by Application (2021-2032)
• 8.3 Europe Fluzoparib Market Size by Country
  • 8.3.1 Europe Fluzoparib Sales Quantity by Country (2021-2032)
  • 8.3.2 Europe Fluzoparib Consumption Value by Country (2021-2032)
  • 8.3.3 Germany Market Size and Forecast (2021-2032)
  • 8.3.4 France Market Size and Forecast (2021-2032)
  • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
  • 8.3.6 Russia Market Size and Forecast (2021-2032)
  • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

• 9.1 Asia-Pacific Fluzoparib Sales Quantity by Type (2021-2032)
• 9.2 Asia-Pacific Fluzoparib Sales Quantity by Application (2021-2032)
• 9.3 Asia-Pacific Fluzoparib Market Size by Region
  • 9.3.1 Asia-Pacific Fluzoparib Sales Quantity by Region (2021-2032)
  • 9.3.2 Asia-Pacific Fluzoparib Consumption Value by Region (2021-2032)
  • 9.3.3 China Market Size and Forecast (2021-2032)
  • 9.3.4 Japan Market Size and Forecast (2021-2032)
  • 9.3.5 South Korea Market Size and Forecast (2021-2032)
  • 9.3.6 India Market Size and Forecast (2021-2032)
  • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
  • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

• 10.1 South America Fluzoparib Sales Quantity by Type (2021-2032)
• 10.2 South America Fluzoparib Sales Quantity by Application (2021-2032)
• 10.3 South America Fluzoparib Market Size by Country
  • 10.3.1 South America Fluzoparib Sales Quantity by Country (2021-2032)
  • 10.3.2 South America Fluzoparib Consumption Value by Country (2021-2032)
  • 10.3.3 Brazil Market Size and Forecast (2021-2032)
  • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

• 11.1 Middle East & Africa Fluzoparib Sales Quantity by Type (2021-2032)
• 11.2 Middle East & Africa Fluzoparib Sales Quantity by Application (2021-2032)
• 11.3 Middle East & Africa Fluzoparib Market Size by Country
  • 11.3.1 Middle East & Africa Fluzoparib Sales Quantity by Country (2021-2032)
  • 11.3.2 Middle East & Africa Fluzoparib Consumption Value by Country (2021-2032)
  • 11.3.3 Turkey Market Size and Forecast (2021-2032)
  • 11.3.4 Egypt Market Size and Forecast (2021-2032)
  • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
  • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

• 12.1 Fluzoparib Market Drivers
• 12.2 Fluzoparib Market Restraints
• 12.3 Fluzoparib Trends Analysis
• 12.4 Porters Five Forces Analysis
  • 12.4.1 Threat of New Entrants
  • 12.4.2 Bargaining Power of Suppliers
  • 12.4.3 Bargaining Power of Buyers
  • 12.4.4 Threat of Substitutes
  • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

• 13.1 Raw Material of Fluzoparib and Key Manufacturers
• 13.2 Manufacturing Costs Percentage of Fluzoparib
• 13.3 Fluzoparib Production Process
• 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

• 14.1 Sales Channel
  • 14.1.1 Direct to End-User
  • 14.1.2 Distributors
• 14.2 Fluzoparib Typical Distributors
• 14.3 Fluzoparib Typical Customers

15 Research Findings and Conclusion

16 Appendix

• 16.1 Methodology
• 16.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Fluzoparib market size was valued at US$ 44.24 million in 2025 and is forecast to a readjusted size of US$ 115 million by 2032 with a CAGR of 7.6% during review period.
Fluzoparib is an oral small-molecule targeted anticancer drug that belongs to the class of poly (ADP-ribose) polymerase (PARP) inhibitors. It works by inhibiting PARP enzyme activity, blocking the repair of single-strand DNA breaks in tumor cells, thereby leading to the accumulation of DNA damage and ultimately inducing tumor cell death. Fluzoparib is mainly used for the treatment of solid tumors such as ovarian cancer and breast cancer in patients with BRCA gene mutations, and it plays an important role in maintenance therapy and the treatment of recurrent tumors. The drug is characterized by convenient oral administration and strong targeting ability, but it may also cause adverse reactions such as anemia, nausea, and fatigue.In 2025, Global Fuzuloparib Production Reached Approximately 1.2 Million units.
Fluzoparib, as a domestically developed PARP inhibitor, has rapidly emerged in China’s targeted anti-tumor therapy market in recent years. Developed by Hengrui Pharmaceuticals, the drug is primarily used for the treatment of BRCA mutation-related tumors such as ovarian cancer, benchmarking against international products like Olaparib. With the advancement of precision medicine and the increasing adoption of genetic testing, the eligible patient population for PARP inhibitors continues to expand, driving sustained growth in demand for fluzoparib. At the same time, inclusion in national medical insurance negotiations has significantly reduced patients’ financial burden and improved drug accessibility, enhancing its competitiveness in the domestic market. From a competitive landscape perspective, fluzoparib has gradually gained market share against imported drugs due to its pricing advantage and strong local distribution channels. However, multiple PARP inhibitors from both domestic and international companies are being launched or are in late-stage clinical development, intensifying market competition. Looking ahead, the growth potential of fluzoparib will largely depend on the expansion of indications (such as breast cancer and prostate cancer), combination therapy strategies, and the accumulation of real-world evidence. Overall, driven by supportive policies and strong clinical demand, the fluzoparib market still holds significant growth potential, although it faces long-term challenges in innovation and differentiation.
This report is a detailed and comprehensive analysis for global Fluzoparib market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Fluzoparib market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Fluzoparib market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Fluzoparib market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Fluzoparib market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Fluzoparib
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Fluzoparib market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Jiangsu Hengrui Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Fluzoparib market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
50 Mg
100 Mg
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Application
Ovarian Cancer Treatment
Breast Cancer
Prostate Cancer
Pancreatic Cancer
Others
Major players covered
Jiangsu Hengrui Pharmaceuticals
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Fluzoparib product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Fluzoparib, with price, sales quantity, revenue, and global market share of Fluzoparib from 2021 to 2026.
Chapter 3, the Fluzoparib competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Fluzoparib breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Fluzoparib market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Fluzoparib.
Chapter 14 and 15, to describe Fluzoparib sales channel, distributors, customers, research findings and conclusion.